Andrew Hindman
Director/Board Member bei BIOTIE THERAPIES CORP
Vermögen: 3 Mio $ am 31.03.2024
Profil
Andrew Asa Hindman is currently a Director at Biotie Therapies Oy.
He was previously the President & Chief Executive Officer at Tobira Therapeutics, Inc. and Senior Vice President-Corporate Development at Gilead Sciences, Inc. He also held the position of Vice President-Corporate Development at Onyx Pharmaceuticals, Inc. and Chief Business Officer at Acorda Therapeutics, Inc. Additionally, he was the Senior Vice President-Corporate Development at Nodality, Inc. Mr. Hindman has an MBA from The Trustees of Columbia University in The City of New York and an MBA from Haas School of Business.
He also has an undergraduate degree from Wesleyan University.
Currently, he is the Chief Financial Officer & Senior Vice President at Theravance Biopharma, Inc.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
THERAVANCE BIOPHARMA INC
0,80% | 06.03.2023 | 384 714 ( 0,80% ) | 3 Mio $ | 31.03.2024 |
Aktive Positionen von Andrew Hindman
| Unternehmen | Position | Beginn |
|---|---|---|
| BIOTIE THERAPIES CORP | Director/Board Member | 01.12.2016 |
Ehemalige bekannte Positionen von Andrew Hindman
| Unternehmen | Position | Ende |
|---|---|---|
| THERAVANCE BIOPHARMA, INC. | Director of Finance/CFO | 31.12.2022 |
| ACORDA THERAPEUTICS, INC. | Corporate Officer/Principal | 31.05.2019 |
Tobira Therapeutics, Inc. /Old/
 Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Chief Executive Officer | 01.01.2014 |
Nodality, Inc.
 Nodality, Inc. BiotechnologyHealth Technology Nodality, Inc. develops bioinformatics tools to enhance drug development process. Its technology profiles signaling networks in single cells by multiparametric phospho-flow cytometry. The company was founded by Michael C. Needels, Omar D. Perez, Garry P. Nolan and Rodney Weldon Turner in 2003 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01.01.2011 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01.01.2008 |
Ausbildung von Andrew Hindman
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
| Wesleyan University | Undergraduate Degree |
| Haas School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| ACORDA THERAPEUTICS, INC. | Health Technology |
| THERAVANCE BIOPHARMA, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Nodality, Inc.
Nodality, Inc. BiotechnologyHealth Technology Nodality, Inc. develops bioinformatics tools to enhance drug development process. Its technology profiles signaling networks in single cells by multiparametric phospho-flow cytometry. The company was founded by Michael C. Needels, Omar D. Perez, Garry P. Nolan and Rodney Weldon Turner in 2003 and is headquartered in San Francisco, CA. | Health Technology |
Biotie Therapies Oy
 Biotie Therapies Oy Pharmaceuticals: MajorHealth Technology Biotie Therapies Oy engages in the research, development, and commercialization of pharmaceutical products. The company was founded by Markku Tapani Jalkanen and Sirpa Tuulikki Jalkanen in June 1992 and is headquartered in Helsinki, Finland. | Health Technology |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Health Technology |
